Abstract
Psychiatric disorders increase the risk of acquiring human immunodeficiency virus (HIV) and increase morbidity from HIV-related illness by impeding treatment. The response to highly active antiretroviral therapies is impaired by poor patient adherence, a substantial component of which is related to mental illness and substance use disorders. The recognition of psychiatric disorders in most HIV clinics is an issue of utmost importance. We outline diagnostic and treatment issues for major depression, bipolar disorder, personality disorder, substance use disorders, and demoralization as seen in patients with HIV. Our experience at the Johns Hopkins Moore (HIV) Clinic has led us to conclude that treatment of these disorders greatly improves patient adherence to treatment and outcomes of HIV infection.
MeSH terms
-
Antidepressive Agents / administration & dosage
-
Antipsychotic Agents / administration & dosage
-
Antiretroviral Therapy, Highly Active
-
Bipolar Disorder / complications
-
Bipolar Disorder / psychology
-
Bipolar Disorder / therapy
-
Depressive Disorder / complications
-
Depressive Disorder / psychology
-
Depressive Disorder / therapy
-
Drug Interactions
-
HIV Infections / complications*
-
HIV Infections / psychology*
-
HIV Infections / therapy
-
Humans
-
Mental Disorders / complications*
-
Mental Disorders / psychology
-
Mental Disorders / therapy*
-
Patient Compliance
-
Personality Disorders / complications
-
Personality Disorders / psychology
-
Personality Disorders / therapy
-
Substance-Related Disorders / complications
-
Substance-Related Disorders / psychology
-
Substance-Related Disorders / therapy
Substances
-
Antidepressive Agents
-
Antipsychotic Agents